Prognostic Value of Heart‐Type Fatty Acid‐Binding Protein in Patients With Acute Coronary Syndrome: A Systematic Review and Meta‐Analysis
Cardiovascular Therapeutics · 2026
DOI: 10.1155/cdr/4836688 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cardiovascular Therapeutics, 2026. Verfasst von Ahmed Elmewafy und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Sheffield, Sheffield, UK, sheffield.ac.uk. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Fatty Acid Binding Protein 3. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Heart‐type fatty acid‐binding protein (H‐FABP) is rapidly released following myocardial injury, but its prognostic significance in acute coronary syndrome (ACS) remains uncertain. We evaluated the association between elevated H‐FABP and adverse clinical outcomes in confirmed or suspected ACS.
Methods
PubMed, Embase, CENTRAL, Web of Science and Scopus were searched from inception to 30 August 2026 without date restriction. Studies assessing diagnostic and/or prognostic relevance of circulating H‐FABP in adults with confirmed or suspected ACS were eligible. Prognostic outcomes included all‐cause mortality, major adverse cardiovascular events (MACE), heart failure (HF)–related hospitalisation and recurrent myocardial infarction (MI). Risk of bias was assessed using QUIPS. Crude odds ratios (ORs) from extractable 2 × 2 event data were pooled using inverse‐variance random‐effects models with restricted maximum‐likelihood estimation.
Results
Twelve studies were included, with five contributing to meta‐analysis. Elevated H‐FABP was associated with higher odds of all‐cause mortality (OR 5.68; 95% CI 3.98–8.09; I 2 = 30 % ), MACE (OR 4.56; 95% CI 1.97–10.55; I 2 = 47 % ), HF‐related hospitalisation (OR 4.29; 95% CI 2.94–6.26; I 2 = 0 % ) and recurrent MI (OR 1.65; 95% CI 1.15–2.37; I 2 = 0 % ). Pooled estimates were unadjusted; seven studies were synthesised narratively.
Conclusion
Elevated H‐FABP is associated with adverse outcomes in ACS, but current evidence does not establish independent prognostic value. Further prospective studies should determine whether H‐FABP adds predictive value beyond established clinical and biochemical risk markers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, University of Sheffield, Sheffield, UK, sheffield.ac.uk.
- Royal Blackburn Teaching Hospital, East Lancashire Hospitals NHS Trust, Blackburn, UK, nhs.uk.
- School of Medicine, Royal College of Surgeons in Ireland, Medical University of Bahrain, Busaiteen, Kingdom of Bahrain, uob.edu.bh.
- School of Medicine, Royal College of Surgeons of Ireland, University of Medicine and Health Sciences, Dublin, Ireland, rcsi.ie.
- School of Medicine, St. George's University, St. George's, Grenada.
- Division of Cardiovascular Sciences, Clinical Science Wing, University of Leicester, Glenfield Hospital, Leicester, UK, nhs.uk.
ORCID-Profile: Ahmed Elmewafy, Eyad Jamileh, Abdullah Hussain, Loay Kamel, Ibrahim Antoun
Zitieren
APA
Elmewafy, A., Jamileh, E., Hussain, A., Kamel, L., Farooq, O., Gamal, H., & Antoun, I. (2026). Prognostic Value of Heart‐Type Fatty Acid‐Binding Protein in Patients With Acute Coronary Syndrome: A Systematic Review and Meta‐Analysis. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/4836688
Vancouver
Elmewafy A, Jamileh E, Hussain A, Kamel L, Farooq O, Gamal H, et al. Prognostic Value of Heart‐Type Fatty Acid‐Binding Protein in Patients With Acute Coronary Syndrome: A Systematic Review and Meta‐Analysis. Cardiovascular Therapeutics. 2026. doi:10.1155/cdr/4836688
BibTeX
@article{Elmewafy2026,
author = {Elmewafy, Ahmed and Jamileh, Eyad and Hussain, Abdullah and Kamel, Loay and Farooq, Omar and Gamal, Hany and Antoun, Ibrahim},
title = {Prognostic Value of Heart‐Type Fatty Acid‐Binding Protein in Patients With Acute Coronary Syndrome: A Systematic Review and Meta‐Analysis},
journal = {Cardiovascular Therapeutics},
year = {2026},
doi = {10.1155/cdr/4836688}
}
EUVIMED